Stay updated on SG + Pembrolizumab in HR+ / HER2- MBC Clinical Trial
Sign up to get notified when there's something new on the SG + Pembrolizumab in HR+ / HER2- MBC Clinical Trial page.

Latest updates to the SG + Pembrolizumab in HR+ / HER2- MBC Clinical Trial page
- Check2 days agoChange DetectedThe page adds a Locations section listing study sites in Georgia, Illinois, Massachusetts, North Carolina, and Pennsylvania, and removes the prior state-location entries; the revision tag updates from v3.3.2 to v3.3.3.SummaryDifference0.6%

- Check9 days agoNo Change Detected
- Check16 days agoNo Change Detected
- Check30 days agoChange DetectedRevision tag updated from v3.2.0 to v3.3.2 on the study page. No substantive changes to study details or eligibility criteria are evident.SummaryDifference0.0%

- Check38 days agoChange DetectedA government funding status notice has been removed from the page; core study details, eligibility criteria, locations, and outcomes remain unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check52 days agoChange DetectedResults from the study have been posted on the page, and the study record dates show updates including 'Results First Posted' on 2025-05-30 and the latest update on 2025-06-25.SummaryDifference0.4%

- Check81 days agoChange DetectedMajor update: adds current operating status notice and links for NIH Clinical Center, and bumps version to v3.2.0, replacing the old v3.1.0.SummaryDifference2%

- Check88 days agoChange DetectedChanged the revision from v3.0.2 to v3.1.0, indicating a new version without other substantive content changes.SummaryDifference0.1%

Stay in the know with updates to SG + Pembrolizumab in HR+ / HER2- MBC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the SG + Pembrolizumab in HR+ / HER2- MBC Clinical Trial page.